Arrive - Abatacept Researched In Rheumatoid Arthritis Patients with An Inadequate Anti-TNF Response To Validate Effectiveness Trademark Details

This mark is dead with a status of Abandoned-Failure to Respond or Late Response. The last case file activity for this mark occured 10 years ago on Wednesday, January 8, 2014, according to the United State Patent & Trademark Office
Word Mark Arrive - Abatacept Researched in Rheumatoid Arthritis Patients with an Inadequate anti-Tnf Response to Validate Effectiveness
Status Dead 602 — Abandoned-Failure to Respond or Late Response

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 77700548
Status Date Wednesday, January 8, 2014
Filing Date Wednesday, January 8, 2014
Attorney Marilyn F. Kelly

Correspondent

Marilyn F. Kelly
BRISTOL-MYERS SQUIBB COMPANY
TRADEMARKS DEPT. - MAILSTOP D33-05
P.O. BOX 4000
PRINCETON NJ 08648-4000

Case File Statements

Disclaimer with Predetermined Text "Abatacept Researched in Rheumatoid Arthritis Patients with an Inadequate.anti-Tnf Response to Validate Effectiveness"
Goods & Services Medical and scientific research, namely, conducting clinical trials relating to pharmaceutical preparations for human use

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Tuesday, March 31, 2009
First Use Anywhere Sunday, April 10, 2005
First Use In Commerce Sunday, April 10, 2005
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.